Abstract
Human ovarian cancer lines were used to compare the efficacy of platinum compounds with the effica cy of cisplatin and that of trimelamol with hexamethylmelamine at maximum tolerated doses. As for cisplatin analogs tested in two lines, carboplatin was shown to be similar in efficacy to cisplatin, followed by iproplatin, JM-40 and TN0-38; tetraplatin and spiroplatin were considered less active. Experimental data correlated well with clinical findings in ovarian cancer currently available for cisplatin, carboplatin, iproplatin and spiroplatin. The slightly lower efficacy of TN0-38 as compared to the parent drug was reconfirmed in 5 other human ovarian cancer lines.
The activity of trimelamol was similar to or higher than that of hexamethylmelamine in 8/9 lines studied. The human ovarian cancer model seems to have considerable value in the selection of analogs with potential activity in this malignancy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Richardson GS, Scully RE, Nikrui N and Nelson JH: Com mon epithelial cancer of the ovary (second of two parts). N Engl J Med 1985 (312): 474–483
Evans BD, Raju KS, Calvert AH, Harland SJ and Wiltshaw E: Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma. Cancer Treat Rep 1983 (67): 997–1000
Creaven PJ, Madajevicz S, Pendyala L, Mittelman A, Pontes E, Spaulding M, Arbuck S and Solomon J: Phase I clinical trial of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum (IV) (CHIP). Cancer Treat Rep 1983 (67): 795–800
Johnson BL, Fisher Rl, Bender RA, DeVita VT, Chabner BA and Young RC: Hexamethylmelamine in alkylating agent-resistant ovarian carcinoma. Cancer 1978 (42): 2157–2161
Bonomi PD, Mladineo J, Morrin B, Wilbanks G and Slayton RE: Phase II trial of hexamethylmelamine in ovarian carcinoma resistant to alkylating agents. Cancer Treat Rep 1979 (63): 137–138
Judson IR, Rutty CJ, Abel G, Gumbrell L, Harrap KR and Calvert AH: Report on the phase I trial of N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine (trimelamol). Br J Cancer 1985 (52): 466
Boven E, Van der Vijgh WJF, Nauta MM, Schlueper HMM and Pinedo HM: Comparative acivity and distribution studies of five platinum analogues in nude mice bearing human ovarian cancer xenografts. Cancer Res 1985 (45): 86–90
Boven E, Nauta MM, Schlueper HMM, Elferink F, Van der Vijgh WJF and Pinedo HM: Secondary screening of platinum compounds in human ovarian cancer xenografts in nude mice. Eur J Cancer Clin Oncol 1985 (21): 1253–1260
Boven E, Nauta MM, Schlueper HMM, Erkelens CAM and Pinedo HM: Superior efficacy of trimelamol to hexamethylmelamine in human ovarian cancer xenografts. Cancer Chemother Pharmacol 1986 (18): 124–128
Vermorken JB, Ten Bokkel Huinink WW, McVie JG, Van der Vijgh WJF and Pinedo HM: Clinical experience with 1,1 -diaminomethylcyclohexane(sulphato)platinum(ll) (TNO-6). In: Hacker MP, Douple EB and Krakoff IH (eds) Platinum coordination complexes in cancer chemotherapy. Boston: Martinus Nijhoff Publishing: 330–343
Ames MM, Sanders ME and Tiede WS: Metabolic activation of hexamethylmelamine and pentamethylmelamine by liver microsomal preparations. Life Sciences 1981 (29): 1591–1598
Rutty CJ, Newell DR, Muindi JRF and Harrap KR: The comparative pharmacokinetics of pentamethylmelamine in man, rat and mouse. Cancer Chemother Pharmacol 1982(8): 105–111
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Boven, E. (1988). Screening of Analogs in Human Ovarian Cancer Xenografts. In: Winograd, B., Peckham, M., Pinedo, H.M. (eds) Human Tumour Xenografts in Anticancer Drug Development. ESO Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73252-2_12
Download citation
DOI: https://doi.org/10.1007/978-3-642-73252-2_12
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-73254-6
Online ISBN: 978-3-642-73252-2
eBook Packages: Springer Book Archive